Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Open access

Abstract

INTRODUCTION: Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or ileocecal junction and cecum (MD-7246, formerly DR2) would modulate linaclotide's secretory effects while preserving pain relief effects. METHODS: This phase 2b study randomized patients with IBS with constipation to placebo or 1 of 7 once-daily linaclotide doses (DR1 30, 100, or 300 μg; MD-7246 30, 100, or 300 μg; or IR 290 μg) for 12 weeks. Key efficacy endpoints were change from baseline in abdominal pain and complete spontaneous bowel movement frequency, and 6/12-week combined APC+1 responder rate. RESULTS: Overall, 532 patients were randomized; mean age was 45.1 years, and most were women (83.3%) and White (64.7%). All linaclotide DR1 and MD-7246 groups experienced greater improvements in abdominal pain from baseline and vs placebo throughout treatment. Linaclotide DR1 and IR led to numerically greater improvements from baseline in complete spontaneous bowel movement frequency and higher APC+1 responder rates compared with placebo; MD-7246 results were similar to placebo. Diarrhea was the most common adverse event with DR1 and IR; rates were similar between MD-7246 and placebo. DISCUSSION: Altering the site of drug delivery in the intestine might uncouple linaclotide's pain relief from secretory effects. Persistent, modest abdominal pain improvement with limited impact on bowel symptom parameters, as seen across MD-7246 doses, warrants further study of MD-7246 as a novel treatment for abdominal pain, regardless of IBS subtype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000000967

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study design. DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; PBO, placebo.
Figure 1. Study design. DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; PBO, placebo.CC BY-NC-ND · PubMed Central
Figure 2. Weekly CFB in abdominal pain. Treatment effects of (a) LIN DR1 30 μg, 100 μg, and 300 μg and (b) MD-7246 30 μg, 100 μg, and 300 μg are shown with respect to LIN 290 μg IR and PBO, with 12-week LS mean differences vs PBO reported in each legend. All 8 treatment groups were evaluated in a single model, wherein treatment group was included as a fixed effect. CFB, change from baseline; CI, confidence interval; DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; LS, least-squares; PBO, placebo.
Figure 2. Weekly CFB in abdominal pain. Treatment effects of (a) LIN DR1 30 μg, 100 μg, and 300 μg and (b) MD-7246 30 μg, 100 μg, and 300 μg are shown with respect to LIN 290 μg IR and PBO, with 12-week LS mean differences vs PBO reported in each legend. All 8 treatment groups were evaluated in a single model, wherein treatment group was included as a fixed effect. CFB, change from baseline; CI, confidence interval; DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; LS, least-squares; PBO, placebo.CC BY-NC-ND · PubMed Central
Figure 3. Weekly CFB in CSBM frequency. Treatment effects of (a) LIN DR1 30 μg, 100 μg, and 300 μg and (b) MD-7246 30 μg, 100 μg, and 300 μg are shown with respect to LIN 290 μg IR and PBO, with 12-week LS mean differences vs PBO reported in each legend.All 8 treatment groups were evaluated in a single model, wherein treatment group was included as a fixed effect. CFB, change from baseline; CI, confidence interval; CSBM, complete spontaneous bowel movement; DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; LS, least-squares; PBO, placebo.
Figure 3. Weekly CFB in CSBM frequency. Treatment effects of (a) LIN DR1 30 μg, 100 μg, and 300 μg and (b) MD-7246 30 μg, 100 μg, and 300 μg are shown with respect to LIN 290 μg IR and PBO, with 12-week LS mean differences vs PBO reported in each legend.All 8 treatment groups were evaluated in a single model, wherein treatment group was included as a fixed effect. CFB, change from baseline; CI, confidence interval; CSBM, complete spontaneous bowel movement; DR1, delayed-release formulation 1; IR, immediate-release formulation; LIN, linaclotide; LS, least-squares; PBO, placebo.CC BY-NC-ND · PubMed Central
Figure 4. Percentage of patients with diarrhea TEAEs, including those leading to discontinuation. The proportion of patients with diarrhea TEAEs leading to discontinuation (grey) is shown as a subset of the total population with ≥1 diarrhea TEAE in each treatment group. DR1, delayed-release formulation 1; IR, immediate-release formulation; TEAE, treatment-emergent adverse event.
Figure 4. Percentage of patients with diarrhea TEAEs, including those leading to discontinuation. The proportion of patients with diarrhea TEAEs leading to discontinuation (grey) is shown as a subset of the total population with ≥1 diarrhea TEAE in each treatment group. DR1, delayed-release formulation 1; IR, immediate-release formulation; TEAE, treatment-emergent adverse event.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 43

Metadata

Authors
Chey, W. D., Sayuk, G. S., Bartolini, W., Reasner, D. S., Fox, S. M., Bochenek, W., Boinpally, R., Shea, E., Tripp, K., & Borgstein, N.
Affiliations
  • Michigan Medicine (US)
  • Washington University in St. Louis (US)
  • Ironwood Pharmaceuticals (United States) (US)
  • Imbria Pharmaceuticals, Boston, Massachusetts, USA;
  • AbbVie (United States) (US)
  • Cyclerion (United States) (US)
Corresponding author
Bartolini, Wilmin
Venue
American Journal of Gastroenterology
Published
2020-10-15
Volume
116
Issue
2
Pages
354-361
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
OpenAlex
W3092931770
Cited by
41
References
27
Citations by year
2026: 3 · 2025: 3 · 2024: 18 · 2023: 1 · 2022: 5 · 2021: 9
FWCI
3.26
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
linaclotide, irritable bowel syndrome with constipation, delayed-release formulation, abdominal pain, diarrhea, once-daily dosing
MeSH terms
Guanylyl Cyclase C Agonists, Adult, Constipation, Defecation, Delayed-Action Preparations, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Peptides, Abdominal Pain, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. https://app.cochat.ai/papers/10.14309/ajg.0000000000000967
The paper
Chey, W. D., Sayuk, G. S., Bartolini, W., Reasner, D. S., Fox, S. M., Bochenek, W., Boinpally, R., Shea, E., Tripp, K., & Borgstein, N. (2021). Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000000967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.